The market is missing the clues here.
All the CEO interviews and company anns talk about European 2B pivotal trial...but also speak to planning US path forward with FDA?
Then there is talk of other indications.
Hello!
How is a an ASX microcap with $9m cash and handful of staff meant to pursue such grand plans?
Maybe cos the dance has started with BigPharma and we will see a flurry of concurrent Combination trials in EU and US?
Otherwise this aggressive posturing in the company messaging...seemingly approved by the Board...makes no sense.
Not long to go now before we step up to next level at +$100m market cap.
One Study Away, page-34
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |